An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Penn Medicine is advancing cancer treatment with its work in CAR T-cell therapy, an innovative immunotherapy that is reshaping the fight against blood cancers and rare genetic diseases. Penn Medicine ...

Despite the powerful cancer-fighting capabilities of treatments based on T cells containing an engineered chimeric antigen receptor (CAR) to fight a patient’s cancer, one key challenge is ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Treatment with the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) continued to demonstrate durable responses after a median follow-up of more than five years in patients with ...